文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

纤维化样肺部影像模式与COVID-19慢性危重症不良结局无关

Fibrotic-Like Pulmonary Radiographic Patterns Are Not Associated With Adverse Outcomes in COVID-19 Chronic Critical Illness.
PubMed 文献 · Crit Care Med · 2023-06-09
一句话结论COVID-19相关ARDS慢性危重症患者中约半数出现纤维化样影像模式,与插管日白介素-6升高相关,但不延长机械通气脱离时间,也不降低6个月生存率。

本研究为单中心前瞻性队列研究,纳入2020年3月至5月收治的COVID-19相关ARDS并进展为慢性危重症(机械通气>21天、气管切开、存活至ICU出院)的成人患者。在ICU出院至出院后30天期间行胸部CT,采用既定方法量化非纤维化与纤维化样模式。616例成人中141例(23%)进展为慢性危重症,其中64例(46%)在插管后中位66天(四分位距42-82天)接受胸部CT;55%存在以网格影和/或牵拉性支气管扩张为特征的纤维化样模式。校正分析显示插管日白介素-6水平与纤维化样模式相关(每四分位变化比值比4.40,95%CI 1.90-10.1),而其他炎症生物标志物、SOFA评分、年龄、潮气量、驱动压和机械通气天数无此关联。纤维化样模式与机械通气脱离时间延长或6个月生存率降低无关。

要点

  • COVID-19相关ARDS慢性危重症(机械通气>21天、气管切开、存活至ICU出院)患者中,141/616例(23%)进展为慢性危重症,其中64/141例(46%)接受胸部CT。
  • 64例接受CT者中55%存在纤维化样模式,特征为网格影和/或牵拉性支气管扩张。
  • 校正分析中,插管日白介素-6每四分位变化与纤维化样模式相关(比值比4.40,95%CI 1.90-10.1)。
  • 其他炎症生物标志物、SOFA评分、年龄、潮气量、驱动压和机械通气天数与纤维化样模式无关联。
  • 纤维化样模式与机械通气脱离时间延长或6个月生存率降低无关。

适用人群与场景

  • 2020年3月至5月期间收治的COVID-19相关ARDS并进展为慢性危重症的成人患者,慢性危重症定义为机械通气>21天、气管切开且存活至ICU出院。

诊断标准与关键阈值

  • 慢性危重症定义:机械通气>21天、气管切开、存活至ICU出院。
  • 纤维化样模式定义为胸部CT上网格影和/或牵拉性支气管扩张。

研究设计与关键结果

  • 研究类型:单中心前瞻性队列研究;共616例COVID-19相关ARDS成人,141例(23%)进展为慢性危重症,其中64例(46%)在插管后中位66天(四分位距42-82天)接受胸部CT。
  • 64例接受CT者中55%存在纤维化样模式(网格影和/或牵拉性支气管扩张)。
  • 校正人口学、合并症和COVID-19治疗后,插管日白介素-6水平与纤维化样模式相关(每四分位变化比值比4.40,95%CI 1.90-10.1)。
  • 其他炎症生物标志物、SOFA评分、年龄、潮气量、驱动压和机械通气天数与纤维化样模式无关联。
  • 纤维化样模式与机械通气脱离时间延长或6个月生存率降低无关联。

证据类型、等级与局限

  • 证据类型:单中心前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于COVID-19相关ARDS慢性危重症患者,纤维化样影像模式不延长机械通气脱离时间,也不降低6个月生存率,不能据此推断不良预后。
  • 插管日白介素-6水平较高者更可能出现纤维化样模式,但其他炎症标志物、SOFA评分、年龄、潮气量、驱动压和机械通气天数与纤维化样模式无关联。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Pulmonary fibrosis is a feared complication of COVID-19. To characterize the risks and outcomes associated with fibrotic-like radiographic abnormalities in patients with COVID-19-related acute respiratory distress syndrome (ARDS) and chronic critical illness.

DESIGN: Single-center prospective cohort study.

SETTING: We examined chest CT scans performed between ICU discharge and 30 days after hospital discharge using established methods to quantify nonfibrotic and fibrotic-like patterns.

PATIENTS: Adults hospitalized with COVID-19-related ARDS and chronic critical illness (> 21 d of mechanical ventilation, tracheostomy, and survival to ICU discharge) between March 2020 and May 2020.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: We tested associations of fibrotic-like patterns with clinical characteristics and biomarkers, and with time to mechanical ventilator liberation and 6-month survival, controlling for demographics, comorbidities, and COVID-19 therapies. A total of 141 of 616 adults (23%) with COVID-19-related ARDS developed chronic critical illness, and 64 of 141 (46%) had a chest CT a median (interquartile range) 66 days (42-82 d) after intubation. Fifty-five percent had fibrotic-like patterns characterized by reticulations and/or traction bronchiectasis. In adjusted analyses, interleukin-6 level on the day of intubation was associated with fibrotic-like patterns (odds ratio, 4.40 per quartile change; 95% CI, 1.90-10.1 per quartile change). Other inflammatory biomarkers, Sequential Organ Failure Assessment score, age, tidal volume, driving pressure, and ventilator days were not. Fibrotic-like patterns were not associated with longer time to mechanical ventilator liberation or worse 6-month survival.

CONCLUSIONS: Approximately half of adults with COVID-19-associated chronic critical illness have fibrotic-like patterns that are associated with higher interleukin-6 levels at intubation. Fibrotic-like patterns are not associated with longer time to liberation from mechanical ventilation or worse 6-month survival.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Madahar P, Capaccione KM, Salvatore MM, et al. Fibrotic-Like Pulmonary Radiographic Patterns Are Not Associated With Adverse Outcomes in COVID-19 Chronic Critical Illness. Crit Care Med. 2023. PMID: 37294143. doi:10.1097/CCM.0000000000005954

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。